Latest:
Influencing Factors to Initially Targeting BCMA in MM
Authors
Matthew J. Ehrhardt, MD, MS
Latest:
Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood Cancer
Matthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.
Georges Ayoub, MD, MS
Georges Ayoub, MD, MS is a Research Fellow in Pathology at Brigham and Women's Hospital.
Latest:
Dr Ayoub on an AI Model to Enhance Interpretability of Morphologic Heterogeneity in Glioblastoma
Georges Ayoub, MD, MS, discusses how a supervised deep-learning model trained with expert-labeled data seeks to improve interpretability and diagnostic precision in glioblastoma morphological analysis.
Carmelo Carlo-Stella, MD, PhD
Latest:
Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCL
Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Jerome Zacks, MD
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome
Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Marco Ruella, MD
Marco Ruella, MD, an assistant professor of medicine (hematology-oncology) in the Department of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies at the University of Pennsylvania Perelman School of Medicine; as well as the scientific director of the Lymphoma Program at the Hospital of the University of Pennsylvania
Latest:
Dr Ruella on the Importance of Clinical Trial and Treatment Accessibility for Myeloma
Marco Ruella, MD, discusses ways to develop accessible cancer treatments to more greatly benefit diverse populations of patients with multiple myeloma.